At a glance
A combined research record involving BPC-157 and a TB-500 preparation.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together BPC-157 and a TB-500 preparation. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[1][2][11]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][5][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of BPC-157 + TB-500.
Source-reported adverse effects and cautions
Observations from preclinical and limited clinical literature.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 2 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Phase / Week | Daily Dose (Total Blend) | Each Peptide (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
Route: Subcutaneous injection, once daily[5][6]. This blend contains equal amounts of BPC-157 and TB-500 (5 mg each); every dose drawn provides a 1:1 ratio of both peptides. Frequency: Inject once daily subcutaneously. This schedule uses 3.0 mL dilution to keep per-injection volumes ≥18 units for accurate measurement. Rotate injection sites systematically[7].
Advanced / Aggressive Approach (Acute Injury Support)
| Phase / Week | Daily Dose (Total Blend) | Each Peptide (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Aggressive Load) | 1000 mcg | 500 mcg BPC + 500 mcg TB-500 | 30 units (0.30 mL) |
| Weeks 3–4 (High Load) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
For acute tissue injuries, some protocols suggest a higher initial loading phase[8][9]. This approach uses higher daily doses during the first 4 weeks before tapering to maintenance. Use with caution; robust human dose-finding data remain limited. Note: A small human case series combining BPC-157 and TB-500 for joint injuries reported improved outcomes at higher combined doses (4 mg BPC + 6 mg TB-500 intra-articular) compared to lower doses[8]. However, systemic subcutaneous protocols typically use the ranges above. Treatment duration is generally limited to 8–12 weeks before cycling off to evaluate response[9]. Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support tissue repair, wound healing, and recovery from musculoskeletal injuries[1][3].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if needed).
- Dose Range: 600–1000 mcg total blend daily (300–500 mcg of each peptide).
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily phased approach.
- Start: 600 mcg total daily (300 mcg each peptide) for Weeks 1–2.
- Loading: Increase to 800 mcg daily for Weeks 3–4.
- Maintenance: Return to 600 mcg daily for Weeks 5–8+.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or vigorous shaking.
- Gently swirl/roll until fully dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and stability.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4–6 weeks; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[6][7].
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[13].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[13].
- Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms, flank) to avoid lipohypertrophy[7].
- Apply gentle pressure post-injection; do not rub the site.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with phased dosing (averaging ~700 mcg/day over the cycle).
-
Peptide Vials (BPC-157 + TB-500, 10 mg blend each):
- 8 weeks ≈ 4 vials
- 12 weeks ≈ 6 vials
- 16 weeks ≈ 8 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PubMed — Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
Current Pharmaceutical Design (PubMed) — Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
PMC — Utilizing developmentally essential secreted peptides such as Thymosin Beta-4 for regenerative therapies (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Annals of the New York Academy of Sciences (PubMed) — Thymosin beta 4 and wound healing: new ideas (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
PMC — Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 07
Research publication
PMC — Subcutaneous drug delivery review: pharmacologic considerations (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Source document
A4M — Thymosin Beta-4 professional monograph (opens in a new tab)a4m.com
Back to overview ↑ - 10
Research publication
PubMed — Detection of thymosin beta-4 and related peptides in sport drug testing (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
Journal of Physiology and Pharmacology (PubMed) — BPC-157 activity at very low doses without toxicity in animal studies (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Research publication
Expert Opinion on Biological Therapy (PubMed) — Thymosin beta-4 and its role in wound healing (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 14
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 15
Public health resource
Biomedicines (2022) — Stable gastric pentadecapeptide BPC 157: pleiotropic beneficial activity and neurotransmitter interactions (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 16
- 17
Research publication
Annals of the New York Academy of Sciences (2007) — Thymosin β4: roles in development, repair, and regeneration (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 19
Source document
Bachem Technical Note — Peptide stability and handling guidelines (opens in a new tab)www.bachem.com
Back to overview ↑ - 20
Public health resource
International Journal of Clinical Pharmacy (2013) — Evaluation of maximum beyond-use-date stability of peptide solutions (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 21
Source document
WADA Prohibited List (2024) — Growth factors and peptides prohibited in sport (opens in a new tab)www.wada-ama.org
Back to overview ↑ - 22
Public health resource
Arthroscopy (2025) — Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 23
Research publication
PubMed (2010) — Randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 24
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 25
Public health resource
NCBI Bookshelf — Administration of parenteral medications: best practices (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.